论文部分内容阅读
目的通过观察肾病综合征(NS)免疫治疗前后白细胞介素-4(interleukin-4,IL-4)和IL-10水平的变化,探讨其临床意义。方法以ELISA检测52例NS患者在接受强的松和环磷酰胺治疗前及4周后血清IL-4和IL-10水平。结果NS患者血清IL-4水平显著增高(P<0.01),并与血清β_2微球蛋白呈显著正相关(n=52,r=0.352.P<0.05),血清IL-10水平与健康人无显著差异。治疗4周后血清IL-4和IL-10水平显著降低(P<0.05),尿蛋白排出量显著低于治疗前(P<0.05)。结论IL-4、IL-10参与了NS发病过程,强的松和环磷酰胺可通过调节IL-4和IL-10产生而调节NS的免疫紊乱,NS的免疫治疗方案可根据细胞因子水平(包括抗炎细胞因子IL-4和IL-10)调整。
Objective To investigate the clinical significance of interleukin-4 (IL-4) and interleukin-10 (IL-10) levels in patients with nephrotic syndrome (NS) before and after immunotherapy. Methods Serum levels of IL-4 and IL-10 were measured in 52 NS patients before and after prednisone and cyclophosphamide treatment. Results Serum levels of IL-4 were significantly increased in patients with NS (P <0.01), and positively correlated with serum β_2 microglobulin (n = 52, r = 0.352, P <0.05) Significant differences. Serum levels of IL-4 and IL-10 were significantly decreased 4 weeks after treatment (P <0.05), and urinary protein excretion was significantly lower than before treatment (P <0.05). Conclusions IL-4 and IL-10 are involved in the pathogenesis of NS. Prednisone and cyclophosphamide can regulate the immune disorders of NS by regulating the production of IL-4 and IL-10. The immunotherapy regimen of NS can be based on the level of cytokines Including anti-inflammatory cytokines IL-4 and IL-10).